ATE499088T1 - Glp-1-fc fusionsprotein-formulierung - Google Patents
Glp-1-fc fusionsprotein-formulierungInfo
- Publication number
- ATE499088T1 ATE499088T1 AT08772467T AT08772467T ATE499088T1 AT E499088 T1 ATE499088 T1 AT E499088T1 AT 08772467 T AT08772467 T AT 08772467T AT 08772467 T AT08772467 T AT 08772467T AT E499088 T1 ATE499088 T1 AT E499088T1
- Authority
- AT
- Austria
- Prior art keywords
- glp
- fusion protein
- protein formulation
- formulation
- polysorbate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94885507P | 2007-07-10 | 2007-07-10 | |
PCT/US2008/069473 WO2009009562A2 (en) | 2007-07-10 | 2008-07-09 | Glp-1-fc fusion protein formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE499088T1 true ATE499088T1 (de) | 2011-03-15 |
Family
ID=39870243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT08772467T ATE499088T1 (de) | 2007-07-10 | 2008-07-09 | Glp-1-fc fusionsprotein-formulierung |
Country Status (19)
Country | Link |
---|---|
US (1) | US20100196405A1 (de) |
EP (1) | EP2175834B8 (de) |
JP (1) | JP2010533197A (de) |
KR (1) | KR20100020516A (de) |
CN (1) | CN101730523A (de) |
AT (1) | ATE499088T1 (de) |
AU (1) | AU2008275180A1 (de) |
BR (1) | BRPI0813699B1 (de) |
CA (1) | CA2691695C (de) |
DE (1) | DE602008005155D1 (de) |
EA (1) | EA201070121A1 (de) |
HK (1) | HK1141237A1 (de) |
HR (1) | HRP20110242T1 (de) |
MX (1) | MX2010000380A (de) |
NZ (1) | NZ582480A (de) |
RS (1) | RS52378B (de) |
UA (1) | UA97673C2 (de) |
WO (1) | WO2009009562A2 (de) |
ZA (1) | ZA201000149B (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2525787B1 (de) | 2010-01-19 | 2017-03-15 | Hanmi Science Co., Ltd. | Flüssige formulierungen für ein g-csf-konjugat mit langzeitwirkung |
JP5800527B2 (ja) * | 2010-03-30 | 2015-10-28 | 日東電工株式会社 | 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法 |
CN102533655A (zh) * | 2010-12-21 | 2012-07-04 | 青岛黄海制药有限责任公司 | 高效表达人源重组蛋白GLP1/Fc的CHO-S细胞株及其建立方法 |
AU2012267398B2 (en) | 2011-06-10 | 2016-10-13 | Hanmi Science Co., Ltd. | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
RU2733544C2 (ru) | 2011-06-17 | 2020-10-05 | Ханми Сайенс Ко., Лтд. | Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение |
US9580479B2 (en) * | 2012-07-20 | 2017-02-28 | University—Industry Cooperation Group Of Kyung Hee University | Peptide tag and uses thereof |
AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
US10441665B2 (en) | 2012-07-25 | 2019-10-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long acting insulinotropic peptide conjugate |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
AR091902A1 (es) * | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
EA039082B1 (ru) | 2012-11-06 | 2021-12-01 | Ханми Фарм. Ко., Лтд. | Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина |
KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
EP2934569A1 (de) | 2012-12-21 | 2015-10-28 | Sanofi | Exendin-4-derivate |
CN104173275A (zh) * | 2013-05-21 | 2014-12-03 | 深圳翰宇药业股份有限公司 | 度拉鲁肽注射剂及其制备方法 |
EP3080152A1 (de) | 2013-12-13 | 2016-10-19 | Sanofi | Nicht-acylierte exendin-4-peptidanaloga |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
CN104293834B (zh) * | 2014-10-11 | 2018-03-23 | 上海兴迪金生物技术有限公司 | GLP‑1或其类似物与抗体Fc片段融合蛋白的制备方法 |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
AU2016218759B2 (en) * | 2015-02-11 | 2021-11-25 | Gmax Biopharm Llc. | Stabilized solution preparation of pharmaceutical GLP-1R antibody fusion protein |
AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
CN107661288A (zh) * | 2016-07-29 | 2018-02-06 | 江苏泰康生物医药有限公司 | 含有glp‑1 类似物融合蛋白的稳定液体制剂及其制备 |
CN107698684B (zh) * | 2016-08-03 | 2021-09-28 | 广东东阳光药业有限公司 | 包含突变的免疫球蛋白Fc部分的GLP-1融合蛋白 |
CN108210890A (zh) * | 2016-12-09 | 2018-06-29 | 江苏泰康生物医药有限公司 | 重组人胰高血糖素样肽-1类似物融合蛋白的新型稳定制剂 |
GB201621987D0 (en) * | 2016-12-22 | 2017-02-08 | Archer Virgil L See Archer Sheri A Arecor Ltd | Novel composition |
HUE063776T2 (hu) | 2017-06-01 | 2024-01-28 | Lilly Co Eli | Dulaglutid krónikus vesebetegség kezelésére |
WO2019035010A1 (en) * | 2017-08-15 | 2019-02-21 | Kindred Biosciences, Inc. | IGG VARIANTS FOR VETERINARY USE |
MX2020005231A (es) * | 2017-11-21 | 2020-08-24 | Lilly Co Eli | Metodos de uso y composiciones que contienen dulaglutida. |
CN116143939A (zh) * | 2017-11-24 | 2023-05-23 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多重活性蛋白 |
TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
CA3128522C (en) | 2019-03-15 | 2024-04-02 | Eli Lilly And Company | Preserved formulations |
CA3177693A1 (en) | 2019-04-05 | 2020-10-05 | Eli Lilly And Company | Therapeutic uses of dulaglutide |
GB201917723D0 (en) * | 2019-12-04 | 2020-01-15 | Nv Rose Llc | Stable liquid formulations of glucagon-like peptide 1 or analogues thereof |
KR102349717B1 (ko) * | 2020-03-12 | 2022-01-11 | 주식회사 에스엘메타젠 | 신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물 |
CN114053217B (zh) * | 2020-08-03 | 2023-04-18 | 华兰生物工程股份有限公司 | 一种Exendin-4-Fc融合蛋白注射制剂及其制备方法 |
CN112494658A (zh) * | 2020-12-04 | 2021-03-16 | 苏桥生物(苏州)有限公司 | 一种稳定的Fc融合蛋白制剂 |
CN114685644A (zh) | 2020-12-29 | 2022-07-01 | 苏州康宁杰瑞生物科技有限公司 | 一种人glp-1多肽变体及其应用 |
CA3224575A1 (en) | 2021-07-06 | 2023-01-12 | Suzhou Alphamab Co., Ltd. | Fusion protein and application thereof |
CN117143242B (zh) * | 2023-10-30 | 2024-03-29 | 南京佰抗生物科技有限公司 | 抗Galectin-3蛋白的单克隆抗体组合物及应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006068910A1 (en) * | 2004-12-22 | 2006-06-29 | Eli Lilly And Company | Glp-1 analog fusion protein formulations |
-
2008
- 2008-07-09 US US12/665,053 patent/US20100196405A1/en not_active Abandoned
- 2008-07-09 BR BRPI0813699-8A patent/BRPI0813699B1/pt active IP Right Grant
- 2008-07-09 KR KR1020107000435A patent/KR20100020516A/ko not_active Application Discontinuation
- 2008-07-09 NZ NZ582480A patent/NZ582480A/en unknown
- 2008-07-09 EP EP08772467A patent/EP2175834B8/de active Active
- 2008-07-09 AT AT08772467T patent/ATE499088T1/de not_active IP Right Cessation
- 2008-07-09 EA EA201070121A patent/EA201070121A1/ru unknown
- 2008-07-09 CA CA2691695A patent/CA2691695C/en active Active
- 2008-07-09 CN CN200880023539A patent/CN101730523A/zh active Pending
- 2008-07-09 AU AU2008275180A patent/AU2008275180A1/en not_active Abandoned
- 2008-07-09 DE DE602008005155T patent/DE602008005155D1/de active Active
- 2008-07-09 RS RS20110188A patent/RS52378B/en unknown
- 2008-07-09 WO PCT/US2008/069473 patent/WO2009009562A2/en active Application Filing
- 2008-07-09 UA UAA201000210A patent/UA97673C2/ru unknown
- 2008-07-09 MX MX2010000380A patent/MX2010000380A/es active IP Right Grant
- 2008-07-09 JP JP2010516211A patent/JP2010533197A/ja not_active Withdrawn
-
2010
- 2010-01-08 ZA ZA2010/00149A patent/ZA201000149B/en unknown
- 2010-08-13 HK HK10107722.8A patent/HK1141237A1/xx unknown
-
2011
- 2011-04-04 HR HR20110242T patent/HRP20110242T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010533197A (ja) | 2010-10-21 |
NZ582480A (en) | 2011-03-31 |
AU2008275180A1 (en) | 2009-01-15 |
BRPI0813699A2 (pt) | 2014-12-30 |
HK1141237A1 (en) | 2010-11-05 |
WO2009009562A3 (en) | 2009-07-09 |
KR20100020516A (ko) | 2010-02-22 |
CA2691695A1 (en) | 2009-01-15 |
MX2010000380A (es) | 2010-03-29 |
CA2691695C (en) | 2014-03-18 |
EP2175834B8 (de) | 2012-08-22 |
RS52378B (en) | 2012-12-31 |
EP2175834A2 (de) | 2010-04-21 |
EA201070121A1 (ru) | 2010-06-30 |
HRP20110242T1 (hr) | 2011-05-31 |
US20100196405A1 (en) | 2010-08-05 |
ZA201000149B (en) | 2011-04-28 |
EP2175834B1 (de) | 2011-02-23 |
UA97673C2 (ru) | 2012-03-12 |
DE602008005155D1 (de) | 2011-04-07 |
CN101730523A (zh) | 2010-06-09 |
WO2009009562A2 (en) | 2009-01-15 |
BRPI0813699B1 (pt) | 2021-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE499088T1 (de) | Glp-1-fc fusionsprotein-formulierung | |
EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
MY147643A (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder | |
BR0313629B1 (pt) | composiÇço detergente bifÁsica lÍquida aquosa de limpeza pessoal. | |
EA200602062A1 (ru) | Амидосоединения и их применение в качестве фармацевтических средств | |
DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
BRPI0512944A (pt) | agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1 | |
ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
ZA200501128B (en) | Biphasic composition induced by polydextrose | |
CL2007003690A1 (es) | Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas. | |
BRPI0722054A2 (pt) | Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico. | |
ATE464045T1 (de) | Zusammensetzung aus milchsäure und lactoferrin | |
ITTO20050715A1 (it) | Calzatura per la prevenzione e la correzione dell'alluce valgo | |
CL2007000789A1 (es) | Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer. | |
EA200800537A1 (ru) | Маррубиин и композиция для уменьшения храпа, упаковка и методика | |
WO2007095609A3 (en) | Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder | |
ATE458482T1 (de) | Verwendung von amino substituierten benzimidazolen | |
MX2009000800A (es) | Peptidos ciclicos anti-inflamatorios y anti-alergicos. | |
UA95094C2 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства | |
DK1948194T3 (da) | Anvendelse af clodronsyre til behandling af hovsenebenssyndrom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |